AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9015114
Drug: Bovine and
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine and rhesus rotavirus vaccines
Trial: 6829497
Drug: Continuous vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous vindesine (1.2 mg/m2, 5-day infusion, every 3 weeks)
Trial: 6829497
Drug: Continuous vinblastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous vinblastine (1.5 mg/m2/day, every 3 weeks)
Trial: 15598790
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of alcohol daily (two drinks)
Trial: 15598790
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of alcohol (control)
Trial: 11829198
Drug: ISDN ointment
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ISDN ointment (13.4 +/- 3.61 mg ISDN)
Trial: 9780281
Drug: Both G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both G‐CSF and rifabutin
Trial: 8537705
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg orally
Trial: 8537705
Drug: Rifampicin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin therapy
Trial: 2320489
Drug: Sponging plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sponging plus acetaminophen
Trial: 9115527
Drug: Acetaminophen alone
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen alone
Trial: 656286
Drug: Digoxin solution
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin solution alone
Trial: 656286
Drug: Three intact
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intact capsules containing digoxin solution
Trial: 656286
Drug: Three capsules
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three capsules containing digoxin solution sectioned in half
Trial: 656286
Drug: Three capsules
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three capsules containing digoxin solution dissolved in water prior to administration
Trial: 19568027
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of high-dose intravenous therapy followed by 3 weeks of oral therapy
Trial: 19568027
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days or less intravenous treatment
Trial: 19568027
Drug: Shortened course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened course of intravenous and oral antibiotic therapy
Trial: 14722627
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (1000 mg/day for 12 weeks)
Trial: 14722627
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1000 mg/day for 12 weeks)
Trial: 7635409
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN‐alpha) treatment
Trial: 22315495
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day imatinib
Trial: 22315495
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day imatinib
Trial: 22315495
Drug: Imatinib C(min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib C(min) > 1165 ng/mL on Day 29
Trial: 19821004
Drug: 5% ethanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ethanolamine oleate after gelatin sponge administration (group E)
Trial: 17585023
Drug: P125 (1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P125 (1.00 g protein x kg(‐1) x d(‐1))
Trial: 17585023
Drug: P94 (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P94 (0.75 g protein x kg(‐1) x d(‐1))
Trial: 17585023
Drug: P63 (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P63 (0.50 g protein x kg(‐1) x d(‐1))
Trial: 14566492
Drug: Propofol anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia (5-10 mg.kg(‐1).h(‐1))
Trial: 7790243
Drug: AHFX‐S: 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHFX‐S: 1.6 Gy/fraction, twice daily (6‐h interval), 5 days/week, total dose of 67.2 Gy/42 fractions/6 weeks
Trial: 7790243
Drug: AFX‐C: 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFX‐C: 1.8 Gy/fraction/day, 5 daily fractions/week to 54 Gy/30 fractions/6 weeks, total dose of 70.5 Gy/41 fractions/6 weeks
Trial: 2154086
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus sodium restriction (low salt group)
Trial: 2154086
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus hydrochlorothiazide (diuretic group)
Trial: 31385737
Drug: Integrated Psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychological Therapy (IPT) for Treatment-Resistant Schizophrenia (TRS)
Trial: 31385737
Drug: Integrated Psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychological Therapy (IPT) for Nontreatment Resistant Schizophrenia (NTRS)
Trial: 31385737
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) for Nontreatment Resistant Schizophrenia (NTRS)
Trial: 31385737
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) for Treatment-Resistant Schizophrenia (TRS)
Trial: 27465911
Drug: 15 g soy
RxNorm normalized name: SOY ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g soy protein with 66 mg isoflavone (SPI)
Trial: 27465911
Drug: 15 g soy
RxNorm normalized name: SOY ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g soy protein alone (SP)
Trial: 23651878
Drug: MedON (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedON (with antiparkinsonian medication)
Trial: 23651878
Drug: MedOFF (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedOFF (without antiparkinsonian medication)
Trial: 15471991
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg daily dose of aspirin
Trial: 15471991
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg daily dose of aspirin
Trial: 15471991
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg daily dose of aspirin
Trial: 15471991
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three aspirin doses
Trial: 11697842
Drug: E7070 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7070 at 200 mg/m2/day
Trial: 11697842
Drug: E7070 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7070 at 160 mg/m2/day
Trial: 11697842
Drug: E7070 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7070 at 130 mg/m2/day
Trial: 11697842
Drug: E7070 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7070 (various doses)
Trial: 9593027
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg twice daily for 3 weeks)
Trial: 9593027
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg twice daily for 12 months)
Trial: 7930727
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with pneumococcal vaccine
Trial: 3294594
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg three times a day)
Trial: 3294594
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg three times a day) + Nifedipine (20 mg tablet twice a day)
Trial: 3294594
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg tablet twice a day)
Trial: 3294594
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg tablet twice a day) + Captopril (25 mg three times a day)
Trial: 17889863
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (aspirin)
Trial: 10389557
Drug: Subcutaneous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lignocaine
Trial: 8550787
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (0.02 mg/kg BW.day, sc)
Trial: 6308965
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ampicillin, methicillin, and netilmicin (AMN)
Trial: 25846344
Drug: Celecoxib 6
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 6 mg·kg(‐1) preoperatively, followed by 3 mg·kg(‐1) twice daily for five doses
Trial: 23078753
Drug: Maxillary sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary sinus lifting with autogenous bone augmentation and implant insertion at 6 months post grafting (Group I)
Trial: 23078753
Drug: Maxillary sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary sinus lifting with autogenous bone augmentation mixed with PRP (Group II)
Trial: 22048171
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 20/20F at Months 0,6 (n=240)
Trial: 22048171
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 40/40F at Months 0,6 (n=241)
Trial: 22048171
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 40/40F at Months 0,2 (n=240)
Trial: 22048171
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 20/20F at Months 0,1,6 (licensed schedule, n=239)
Trial: 19537094
Drug: Panavir (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panavir (monotherapy for chronic TBE; n = 30)
Trial: 19537094
Drug: Panavir (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panavir (combined therapy for acute TBE; n = 113)
Trial: 10381769
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg MDMA
Trial: 25845448
Drug: Andolast 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andolast 2 mg t.i.d.
Trial: 25845448
Drug: Andolast 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andolast 4 mg t.i.d.
Trial: 25845448
Drug: Andolast 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andolast 8 mg t.i.d.
Trial: 21451140
Drug: α(1)-blocker (prazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α(1)-blocker (prazosin, 1 mg/20 kg body mass)
Trial: 21451140
Drug: α(1)-blocker (prazosin)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: α(1)-blocker (prazosin)
Trial: 1539466
Drug: Recombinant B
RxNorm normalized name: Recombinant BCG Vaccine
DrugBank: VPM1002 (DB15801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant B subunit-whole cell cholera vaccine
Trial: 1539466
Drug: Old type
RxNorm normalized name: Cheese, mold type specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old type B subunit-whole cell cholera vaccine
Trial: 31789482
Drug: 25-hydroxy vitamin
RxNorm normalized name: 1α-hydroxy-vitamin D3
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxy vitamin D (25(OH)D) levels in the lowest tertile (<11 ng/mL)
Trial: 31789482
Drug: FGF-23 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF-23 levels in the highest tertile (>3750 RU/mL)
Trial: 30593883
Drug: Phenotype-stratified clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenotype-stratified clinical trial (Steroids in Eosinophil Negative Asthma - SIENA)
Trial: 27937046
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point dry needling in addition to personalized, evidence-based physical therapy treatment
Trial: 27937046
Drug: Personalized, evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized, evidence-based physical therapy treatment
Trial: 24929431
Drug: Liraglutide (GLP-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (GLP-1 receptor agonist)
Trial: 355024
Drug: Placebo (tablets)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets)
Trial: 11054648
Drug: Placebo (injections)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (injections)
Trial: 6406435
Drug: Bupropion 300
RxNorm normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 300 mg/day
Trial: 19947274
Drug: Chinese herb
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herb medicine of Gentongping (medicine group)
Trial: 19947274
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (DAP and medicine)
Trial: 17434847
Drug: Enfuvirtide-based therapy
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide-based therapy
Trial: 15309728
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy combined with hyperthermia or activated carbon particles
Trial: 12002878
Drug: Unilateral injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral injections of botulinum toxin
Trial: 12002878
Drug: Bilateral injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injections of botulinum toxin
Trial: 8011011
Drug: Analgesic medications
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic medications
Trial: 28408243
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg per day and bevacizumab 15 mg/kg every 21 days
Trial: 23497601
Drug: CTC (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC (with reduced cathartic preparation and standard bowel preparation)
Trial: 21473962
Drug: Prasugrel pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel pretreatment (30 mg after diagnosis + 30 mg at PCI)
Trial: 21473962
Drug: Prasugrel non-pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel non-pretreatment (60 mg at PCI)
Trial: 21473962
Drug: Prasugrel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (5 or 10 mg daily)
Trial: 19551471
Drug: Usual CC
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual CC
Trial: 11226995
Drug: Oral isosmolar
RxNorm normalized name: Watersoluble, nephrotropic, high osmolar X-ray contrast media
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosmolar solution of electrolytes (ISE) administered at a volume of 4 mL/kg 3 hours before completing the fasting period
Trial: 8989424
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms of immunogen (high dose)
Trial: 8989424
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of immunogen (low dose)
Trial: 3122517
Drug: Rivanol with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivanol with balloon catheter and oxytocin infusion
Trial: 29915852
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion with sevoflurane anesthesia (Group S-M)
Trial: 29915852
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion with desflurane anesthesia (Group D-M)
Trial: 24472401
Drug: new combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new combined formulation (olmesartan medoxomil + HCTZ)
Trial: 24472401
Drug: co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-administration of separate tablets (reference drugs)
Trial: 22334811
Drug: Open-label fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label fluoxetine (FLX)
Trial: 21102998
Drug: Gaboxadol 15
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol 15 mg (GBX)
Trial: 21102998
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg (ZOL)
Trial: 18203893
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g EPA plus high-oleic sunflower oil (HOS)
Trial: 16437727
Drug: Amoxicillin, clarithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, clarithromycin, lansoprazole (Group 1)
Trial: 12939213
Drug: Abciximab treatment
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab treatment (n=1052)
Trial: 12939213
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no abciximab treatment, n=1030)
Trial: 10999156
Drug: Granulocyte macrophage
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte macrophage colony stimulating factor (GMCSF) 150 mcg subcutaneously 24 hours prior to vaccination
Trial: 10999156
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received standard three doses of 40 mcg hepatitis B vaccine monthly
Trial: 8697829
Drug: Prednisone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.75 mg/kg/d for up to 4 weeks with gradual reduction over an additional 2 weeks)
Trial: 24247275
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention (INT) including pharmacist-led medication reconciliation, patient education, collaborative care, and voice messaging.
Trial: 24247275
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention (INT) for β-blockers adherence.
Trial: 22947594
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate long-acting injection (PP-LAI)
Trial: 15187573
Drug: Quinapril (high-tissue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (high-tissue penetrating ACE inhibitor)
Trial: 15187573
Drug: Enalapril (low-tissue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (low-tissue penetrating ACE inhibitor)
Trial: 10489384
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg orally)
Trial: 1945319
Drug: Programs that
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programs that determine thresholds only twice at a given location
Trial: 7021041
Drug: L-dopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (500 mg, orally)
Trial: 7021041
Drug: L-dopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (100 mg, orally) plus carbidopa (35 mg, orally) after pretreatment with carbidopa (50 mg every 6 h for four doses)
Trial: 24472224
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet formulations of azithromycin and chloroquine (AZCQ) administered at approximately 30 mg/kg AZ and 10 mg/kg CQ once daily for 3 days in children.
Trial: 24472224
Drug: Two AZCQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two AZCQ tablets (AZ/CQ 250/155 mg per tablet) in adults.
Trial: 24472224
Drug: Individual commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual commercial tablets of azithromycin 500 mg and chloroquine 300 mg in adults.